About Aier Eye Hospital Group Company

The company was founded in 2002, with a medical network in Asia, Europe and North America, and was listed in Shenzhen, China in 2009; the company's branches in Europe and Southeast Asia were listed in Madrid, Spain (CBAV.MC) and Singapore (SGX: 40T), respectively. At this stage, the company adheres to the strategic policy of taking domestic medical development as the main line, combining domestic and international efforts to advance together, introducing and absorbing internationally synchronized ophthalmology technology and medical management concepts, promoting the development of the Chinese ophthalmology industry with a specialized, large-scale, and scientific model, and striving to raise the overall level of ophthalmology care in China and spread the world around the world. As a professional ophthalmology chain medical institution, the company is mainly engaged in diagnosis and treatment of various ophthalmic diseases, surgical services, and medical optometry equipment. Currently, the medical network covers mainland China, Hong Kong, Europe, the United States, and Southeast Asia, establishing a strategic pattern for global development. Main products: Smart glasses for children's eyesight management “Xiaoqingui”, large vertical ophthalmology model AIerGPT, Eyecho (Eyecho), “AiE Science”, etc. Corporate honors: Aier Ophthalmology also won the top ten “Listed Companies Most Respected by Investors” in China, Aier Ophthalmology won the Best Sustainable Investment Value Award, the Most Influential Listed Company Leader Award, Gold Medal, Aier Ophthalmology won the 2017 China Listed Company Best Shareholder Return Award, Aier Ophthalmology was listed among the top 500 Chinese and world brands, and Aier Ophthalmology won the 2021 “China Red Cross Contribution Medal”.